All In Biotech

BLA 761085 · Evolus INC

Jeuveau

Prabotulinumtoxina-Xvfs · Injection · Acetylcholine Release Inhibitor; Neuromuscular Blocker

Novel

Last checked: Nov 20, 2026Latest source record: Jul 12, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Feb 1, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

0 Phase 3, 2 recruiting

FAERS reports

3,779

61 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines. [ See Warnings and Precautions ( 5.1 ) ] WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life...

What it is approved for

From the label in effect Apr 28, 2023.

JEUVEAU is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. JEUVEAU is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients ( 1 )

Mechanism: JEUVEAU blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, JEUVEAU produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • JEUVEAU · PRABOTULINUMTOXINA-XVFS 100 UNITS · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Prabotulinumtoxina" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,590
  • off label use1,315
  • therapeutic product effect decreased715
  • drug effect less than expected469
  • headache171
  • injection site pain114
  • patient dissatisfaction with treatment105
  • injection site swelling99
  • eyelid ptosis73
  • inappropriate schedule of product administration72
  • injection site erythema67
  • product preparation issue59

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191,156
2020749
2021199
2022175
2023273
2024326
2025406
2026495

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Evolus INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.